3 months ago
Natural Molecule Offers New Hope for Managing Chronic Pain
Rutgers University researchers have made a significant breakthrough in the realm of pain management with the identification of a natural molecule that could revolutionize the treatment of chronic pain.
A study conducted by Matthew Gabrielle, a doctoral student in Professor Tibor Rohacs’ lab at Rutgers New Jersey Medical School, reveals that a natural substance known as phosphatidic acid has the potential to modulate pain sensitivity.
Know More: https://thelifesciencesmag...
#naturalmolecule #chronicpain #PainManagement #newhope #MedicalBreakthrough #Innovation #science #health #Wellness #HealthCare #research #discovery #PainRelief
Rutgers University researchers have made a significant breakthrough in the realm of pain management with the identification of a natural molecule that could revolutionize the treatment of chronic pain.
A study conducted by Matthew Gabrielle, a doctoral student in Professor Tibor Rohacs’ lab at Rutgers New Jersey Medical School, reveals that a natural substance known as phosphatidic acid has the potential to modulate pain sensitivity.
Know More: https://thelifesciencesmag...
#naturalmolecule #chronicpain #PainManagement #newhope #MedicalBreakthrough #Innovation #science #health #Wellness #HealthCare #research #discovery #PainRelief
Phosphatidic Acid Offers Hope In Chronic Pain Treatment | The Lifesciences Magazine
Phosphatidic acid identified by Rutgers researchers as a potential key to reducing pain sensitivity, paving the way for innovative chronic pain management therapies.
https://thelifesciencesmagazine.com/phosphatidic-acid-for-chronic-pain/
4 months ago
FDA Approves Durvalumab for Advanced Endometrial Cancer Treatment
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s drug Durvalumab (IMFINZI®) for the treatment of primary advanced or recurrent endometrial cancer in patients with mismatch repair deficiency.
Endometrial cancer is recognized as the most common gynecologic cancer in the United States, with an estimated 66,200 new cases in 2023 alone.
Know More: https://thelifesciencesmag...
#FDAApproval #Durvalumab #EndometrialCancer #CancerTreatment #DrugApproval #MedicalBreakthrough #oncology
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s drug Durvalumab (IMFINZI®) for the treatment of primary advanced or recurrent endometrial cancer in patients with mismatch repair deficiency.
Endometrial cancer is recognized as the most common gynecologic cancer in the United States, with an estimated 66,200 new cases in 2023 alone.
Know More: https://thelifesciencesmag...
#FDAApproval #Durvalumab #EndometrialCancer #CancerTreatment #DrugApproval #MedicalBreakthrough #oncology
Durvalumab Gains FDA Approval For Endometrial Cancer Treatment | The Lifesciences Magazine
Durvalumab (IMFINZI®) approved by FDA for advanced endometrial cancer. Discover its PD-L1 targeting mechanism and its impact on cancer immunotherapy.
https://thelifesciencesmagazine.com/durvalumab-gains-fda-approval/
4 months ago
New Tool Predicts Neurological Outcomes After Cardiac Arrest
Researchers at Osaka Metropolitan University have created a groundbreaking scoring model that accurately forecasts neurological outcomes for patients experiencing out-of-hospital cardiac arrest (OHCA) using only prehospital resuscitation data.
Read More: https://thelifesciencesmag...
#CardiacArrest #neurological #MedicalBreakthrough #HealthCare #PredictionTool #BrainHealth #CardiacScience #PatientCare #HealthTech #Innovation #research
Researchers at Osaka Metropolitan University have created a groundbreaking scoring model that accurately forecasts neurological outcomes for patients experiencing out-of-hospital cardiac arrest (OHCA) using only prehospital resuscitation data.
Read More: https://thelifesciencesmag...
#CardiacArrest #neurological #MedicalBreakthrough #HealthCare #PredictionTool #BrainHealth #CardiacScience #PatientCare #HealthTech #Innovation #research
OHCA Forecast Model Enhances Neurological Outcomes Accuracy | The Lifesciences Magazine
Discover how the new OHCA scoring model by Osaka researchers predicts neurological outcomes using prehospital data, improving patient care and resource allocation.
https://thelifesciencesmagazine.com/ohca-model-for-neurological-outcomes/
